We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Preconceptional Counselling in Active Rheumatoid Arthritis (PreCARA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01345071
Recruitment Status : Recruiting
First Posted : April 29, 2011
Last Update Posted : April 28, 2016
Sponsor:
Collaborators:
Erasmus Medical Center
Dutch Arthritis Association
Information provided by (Responsible Party):
J.M.W. Hazes, Erasmus Medical Center

Brief Summary:
The first objective of the study is to evaluate a treat to target treatment strategy in women with moderate to high disease activity of RA and a pregnancy wish, from pre-pregnancy. The treatment strategy is based on deliberate treatment decisions to lower disease activity, including the continuation or start of biological treatment (in particular anti-Tumor Necrosis Factor [anti-TNF]), based on a standard care protocol in the Erasmus MC. The second objective is to evaluate the safety of the use of anti-TNF during pregnancy among women with a rheumatic disease that require the use of anti-TNF before or during pregnancy.

Condition or disease
Rheumatoid Arthritis Pregnancy

  Show Detailed Description

Study Type : Observational
Estimated Enrollment : 150 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: PreConceptional Counselling in Active Rheumatoid Arthritis
Study Start Date : September 2011
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : May 2025

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort
RA patients
RA patients with active disease or current use of anti-TNF. Treatment is according to treat to target principles.



Primary Outcome Measures :
  1. DAS28(3)CRP at all study points [ Time Frame: Every 3 months from baseline till 6 months after delivery ]

Secondary Outcome Measures :
  1. Time to pregnancy [ Time Frame: At baseline and every 3 months till pregnant ]
    Patient is asked whether is she is pregnant. Pregnancy is defined as positive pregnancy test or ultrasound.

  2. Number of miscarriages [ Time Frame: After conception, every 3 months ]
    Patients normally report miscarriages spontaneously at the next visit after miscarriage or contact the research nurse themselves to report this. If not, and patient is not pregnant anymore, reason for ending of pregnancy will be asked.

  3. Complications during pregnancy [ Time Frame: Every 3 months during pregnancy and first visit after delivery ]
    Complications are: hypertensive disorders, pre-eclampsia, diabetes, mode of delivery, hospitalization

  4. Gestational age of child [ Time Frame: First visit after delivery ]
  5. Birth weight of child [ Time Frame: First visit after delivery ]
  6. Congenital malformations [ Time Frame: First visit after delivery ]
  7. Growth of child and tempo of growth during first year [ Time Frame: One year after birth ]
  8. Maternal serum levels of anti-TNF [ Time Frame: Every three months during pregnancy ]
  9. Levels of anti-TNF in cord blood [ Time Frame: Collected at birth ]
  10. Levels of anti-TNF in child [ Time Frame: Every six weeks after birth ]
    Only if anti-TNF in cord blood was above reference value, blood will be drawn from the newborn every six weeks, till anti-TNF-levels are below reference value


Biospecimen Retention:   Samples With DNA
Blood of mother before, during and after pregnancy; cordblood of newborn; blood of newborn if anti-TNF in cord blood was above reference level.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

For first objective: Women with high disease activity of RA and a pregnancy wish.

For second objective: Women with a rheumatic disease that requires the use of anti-TNF before or during pregnancy

Criteria

Inclusion criteria for first objective (150 subjects)

  • Rheumatoid Arthritis according to 2010 ACR/EULAR criteria
  • active pregnancy wish
  • either DAS28(3)CRP > 3.2 or the current use of anti-TNF

Inclusion criteria for second objective (no limit on number of subjects needed, recruitment will end when 150 RA patients have been included)

  • rheumatic disease that requires the use of anti-TNF before or during pregnancy
  • active pregnancy wish

Exclusion criteria:

- none


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01345071


Contacts
Contact: Marieke van Wier, PhD +31 10 7032181 m.vanwier@erasmusmc.nl
Contact: Radboud Dolhain, PhD MD r.dolhain@erasmusmc.nl

Locations
Netherlands
ErasmusMC, University Medical Center Rotterdam, dept. of Rheumatology Recruiting
Rotterdam, Netherlands, 3000CA
Contact: Marieke van Wier, PhD    +31 10 7032181    m.vanwier@erasmusmc.nl   
Principal Investigator: Radboud J. EM Dolhain, PhD         
Sponsors and Collaborators
J.M.W. Hazes
Erasmus Medical Center
Dutch Arthritis Association
Investigators
Principal Investigator: Radboud Dolhain, PhD MD Staff Rheumatologist

Additional Information:
Publications:
Responsible Party: J.M.W. Hazes, Head of the Department, Erasmus Medical Center
ClinicalTrials.gov Identifier: NCT01345071     History of Changes
Other Study ID Numbers: ErasmusMC-MEC-2011-032
First Posted: April 29, 2011    Key Record Dates
Last Update Posted: April 28, 2016
Last Verified: April 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: This will be discussed in the research group

Keywords provided by J.M.W. Hazes, Erasmus Medical Center:
Rheumatoid Arthritis
Pregnancy
Anti-TNF
Preconceptional counselling
Disease activity

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases